NCT00473434View on ClinicalTrials.gov

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone

3mg or 6mg or 9mg or 12mg once daily for 52 weeks

All Listed Sponsors
lead

Janssen-Cilag Pty Ltd

INDUSTRY

NCT00473434 - An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter